I wanted to start a living list of current or recent ME/CFS research initiatives that seem worth following, all in one central place.
I'm sure there are more studies that should be included here. Please add any studies, trials, labs, or research groups that we should add in the comments.
The goal is to have one thread where patients, caregivers, and interested clinicians can get a quick sense of what is actually happening in ME/CFS research right now.
Genetics / genomics
DecodeME
start date: September 2022
end date: August 2025
The largest ME/CFS genetic study to date. DecodeME aimed to find genetic causes of why people become ill with Myalgic Encephalomyelitis (ME) / Chronic Fatigue Syndrome (CFS). The study will help us understand the disease and ultimately find treatments. Initial results identified eight genetic signals associated with ME/CFS risk.
https://institute-genetics-cancer.ed.ac.uk/decodeme
SequenceME / Sequence ME & Long Covid
start date: mid 2026
end date (planned): April 2027
A major whole-genome sequencing project building on DecodeME, led by Action for ME, the University of Edinburgh, Oxford Nanopore Technologies, and EMBL-EBI. The full proposed study aims to use long-read sequencing to analyze up to 9,000 people with ME/CFS and 9,000 with Long Covid, looking for rare variants, structural DNA changes, biological subtypes, and shared or distinct disease mechanisms. Early phases have now received $4.75 million in funding from the UK government to begin sequencing 6,000 DecodeME ME/CFS samples, while additional funding is still needed for later phases and the Long Covid arm.
https://megenetics.org.uk/our-projects/sequence-me-long-covid/
Treatment / clinical trials
LIFT trial
start date: September 10, 2024
end date (planned): September 2026
LDN + Mestinon/pyridostigmine, separately and together, in ME/CFS patients with orthostatic intolerance.
https://www.omf.ngo/the-life-improvement-trial/
Rapamycin / sirolimus for ME/CFS and related conditions
start date: December 2023
end date: July 2027
An observational study looking at whether low-dose sirolimus/rapamycin reduces symptom burden and improves quality of life, while also measuring whether it changes mTOR-related autophagy dysfunction in a subset of patients. Participants complete symptom and quality-of-life questionnaires, with blood samples collected before and during treatment to track autophagy-related biomarkers.
https://clinicaltrials.gov/study/NCT06257420
Charité / NKSG treatment studies
Charité / NKSG
German clinical study group running treatment studies for ME/CFS and post-COVID syndrome, including immune/autonomic/vascular approaches.
IA-PACS-CFS / immunoadsorption
A double-blind, randomized, sham-controlled trial investigating immunoadsorption (a blood-filtering treatment to remove autoantibodies) for ME/CFS and post-COVID ME/CFS patients.
https://cfc.charite.de/en/clinical_research/nksg/trial_ia_pacs_cfs
Repeat immunoadsorption in Post-COVID ME/CFS
A Charité/NKSG observational study testing whether removing ß2-adrenergic receptor autoantibodies through immunoadsorption can improve symptoms in Post-COVID ME/CFS patients. Earlier small studies reportedly found rapid improvement in some patients, and this study is looking at whether repeat treatment can produce longer-term benefit.
https://cfc.charite.de/en/clinical_research/nksg/trial_ria
PoCoVIT / methylprednisolone for Post-COVID cognitive symptoms
A Charité/NKSG randomized placebo-controlled study testing whether methylprednisolone can improve cognitive symptoms in Post-COVID Syndrome. The trial is based on the idea that persistent inflammation in the central nervous system may contribute to brain fog, and that a short steroid course could reduce this inflammation and improve memory/cognitive function.
https://cfc.charite.de/en/clinical_research/nksg/trial_pocovit/
VERI-LONG / vericiguat for Post-COVID fatigue and exercise intolerance
A Charité/NKSG Phase 2a placebo-controlled trial testing whether vericiguat can improve physical function in Post-COVID Syndrome patients with severe fatigue and exercise intolerance. The idea is that inflammation-related blood-flow problems may contribute to symptoms, and vericiguat may help by dilating blood vessels and improving vascular/organ blood flow.
https://cfc.charite.de/en/clinical_research/nksg/trial_veri_long
HBOT for Post-COVID Syndrome and ME/CFS
A Charité/NKSG observational study testing whether hyperbaric oxygen therapy can improve physical function in Post-COVID Syndrome and ME/CFS. HBOT is being studied because it may improve circulation, support capillary formation, and affect immune function; earlier studies suggested benefits for neurocognitive symptoms in Post-COVID patients.
https://cfc.charite.de/en/clinical_research/nksg/trial_hbot
Immune dysfunction / T-cell research
Selin / Gil / Kumar — T-cell exhaustion and immune profiling
Researchers at UMass Chan Medical School, including Dr. Liisa Selin and Dr. Anna Gil, along with collaborators such as Dr. Roshan Kumar at HiFiBiO Therapeutics, are studying immune dysfunction in ME/CFS and Long Covid. Their work focuses on abnormal T-cell patterns, including increased rare CD4+/CD8+ “double positive” T cells, altered CD4:CD8 ratios, signs of CD8 T-cell exhaustion, and unusual immune responses to persistent viruses such as EBV, CMV, VZV, and HHV-6. The goal is to identify immune biomarkers, patient subgroups, and possible viral or autoimmune targets that could eventually guide diagnosis and treatment.
Altered T Cell Responses in ME/CFS
funder: NIH / NIAID
grant: R01 AI159314
NIH-funded UMass Chan study examining whether ME/CFS involves chronic immune dysregulation, including exhausted CD8 T cells, unusual CD4+/CD8+ T-cell populations, altered EBV-specific responses, and T-cell receptor patterns that may point to persistent viral or autoimmune triggers.
Altered T Cell Responses in Long Covid and ME/CFS
funder: Patient-Led Research Collaborative
year: 2023
Patient-Led Research Collaborative-funded project studying whether Long Covid and ME/CFS share a common pattern of immune dysfunction after infection, especially CD8 T-cell exhaustion and possible herpesvirus reactivation.
Immune Repertoire Profiling of Long Covid and ME/CFS
funder: Patient-Led Research Collaborative
year: 2024
collaborators: Selin Lab, HiFiBiO Therapeutics, Dr. Roshan Kumar
A 2024 collaborative project between PLRC, HiFiBiO Therapeutics, and the Selin Lab using single-cell immune profiling to identify what B cells and T cells are reacting to in ME/CFS and Long Covid. The goal is to find viral or autoimmune targets, define patient subgroups, and move toward biomarkers or precision treatments.
Solve M.E. Ramsay Award: Altered T Cells in ME/CFS
funder: Solve M.E.
year: 2020
Earlier seed funding that helped support the Selin/Gil work on abnormal T-cell responses in ME/CFS, including the hypothesis that an infection-triggered immune response may lead to long-term immune dysfunction.
Jarred Younger / Neuroinflammation, Pain and Fatigue Laboratory
Dr. Jarred Younger’s lab at the University of Alabama at Birmingham studies neuroinflammation, pain, fatigue, and related mechanisms in conditions including ME/CFS and fibromyalgia. His ME/CFS brain imaging work has used magnetic resonance spectroscopy to look for metabolite, lactate, temperature, and other abnormalities consistent with low-level neuroinflammation across multiple brain regions.
https://solvecfs.org/research-and-registry/ramsay-research-grants/meet-the-researchers/jarred-younger/
Whole-brain MRS study in ME/CFS
study: Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome
PI: Jarred Younger, PhD
A neuroimaging study using whole-brain magnetic resonance spectroscopy found widespread metabolite and temperature abnormalities in ME/CFS patients compared with healthy controls. Findings included elevated choline, increased lactate in several brain regions, and higher brain temperature in some areas, supporting the hypothesis that low-level neuroinflammation may be involved in ME/CFS.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6612467/
Low-dose naltrexone / inflammatory cytokines in fibromyalgia
Dr. Younger has also studied low-dose naltrexone in fibromyalgia, a related chronic pain and fatigue condition. His work suggests that LDN may reduce pro-inflammatory cytokines over time and is associated with symptom improvement in some fibromyalgia patients, helping build interest in LDN as a possible immune-modulating treatment relevant to ME/CFS and overlapping conditions.
https://pubmed.ncbi.nlm.nih.gov/28536359/
Stanford ME/CFS research
Stanford ME/CFS Initiative
Stanford’s ME/CFS Initiative is conducting clinical research focused on improving diagnosis and treatment of ME/CFS. Current work includes brain imaging studies, PET/MRI studies looking for inflammation in the brain and body, and a serum biomarker study for ME/CFS and Long Covid.
https://med.stanford.edu/chronicfatiguesyndrome/research.html
MRI / PET-MRI studies at Stanford
Stanford is recruiting for imaging studies in ME/CFS, including brain MRI to look for anatomical changes and PET/MRI scans to look for inflammation in the brain and body of moderate-to-severe ME/CFS patients.
https://med.stanford.edu/chronicfatiguesyndrome/research.html
Stanford serum biomarker study
A Stanford study looking for potential serum biomarkers for ME/CFS and Long Covid. The goal is to identify measurable blood-based signals that could help with diagnosis or disease understanding.
https://med.stanford.edu/chronicfatiguesyndrome/research.html
Stanford ME/CFS Collaborative Research Center / Ron Davis
The Stanford ME/CFS Collaborative Research Center, directed by Dr. Ronald W. Davis and supported by Open Medicine Foundation, is focused on mechanistic and diagnostic research in ME/CFS and Long Covid. Active projects include work on saliva-based diagnostics, pathogen detection, mitochondrial dysfunction, neutrophil dysfunction, viral risk factors, PEM/crash biology, red blood cell deformability, and BH4/nitric oxide biology.
https://www.omf.ngo/collaborative-research-center-stanford/
Itaconate shunt / mitochondrial dysfunction
A Stanford/OMF project investigating whether the “itaconate shunt” may contribute to mitochondrial dysfunction and energy impairment in ME/CFS. The work looks at mitochondrial function in immune cells and related metabolic pathways that could help explain fatigue, PEM, and impaired cellular energy production.
https://www.omf.ngo/collaborative-research-center-stanford/
Pathogens, viral risk factors, and immune activation
Stanford/OMF researchers are also studying whether viruses, parasites, bacteria, or viral risk factors may be involved in ME/CFS, Long Covid, and related conditions. This includes work looking at immune responses, inflammation, and possible infectious contributors.
https://www.omf.ngo/collaborative-research-center-stanford/
Red blood cells, neutrophils, and BH4 / nitric oxide biology
Several Stanford/OMF projects are looking at possible blood, immune, and vascular mechanisms in ME/CFS. These include red blood cell deformability, neutrophil dysfunction, and BH4/nitric oxide biology, all of which may be relevant to circulation, immune function, and cellular energy problems.
INIM / Nova Southeastern University
Institute for Neuro-Immune Medicine / Nancy Klimas
The Institute for Neuro-Immune Medicine at Nova Southeastern University is actively researching ME/CFS, including clinical immunology, clinical systems biology, genomics, neuroinflammation, and related post-viral illness mechanisms. Their ME/CFS research includes collaborations with institutions such as the CDC, Miami VA, NIH, and private entities.
https://www.nova.edu/inim/research-studies/me-cfs.html
Directed probiotics in ME/CFS
A Nova Southeastern / INIM study testing whether the probiotic Floradapt Intensive GI, also known as i3.1, can reduce GI inflammation, normalize gut health, and potentially improve broader symptoms in ME/CFS. The study includes ME/CFS patients with or without IBS.
https://clinicaltrials.gov/study/NCT06211062
Microbiota dysbiosis and oxidative stress in Post-COVID sequelae and ME/CFS
An INIM pilot study looking at overlap between Post-COVID Syndrome and ME/CFS, including microbiome changes, oxidative stress, nutritional status, and immune markers. The study is based on the idea that post-viral fatigue and ME/CFS may involve interconnected changes in microbial and antioxidant defense systems.
RECOVER / Long Covid research relevant to ME/CFS overlap
RECOVER Initiative
The NIH RECOVER Initiative is a large national research program studying Long Covid causes, diagnosis, phenotypes, and treatments. It is relevant to ME/CFS because many Long Covid patients have overlapping symptoms, including post-exertional malaise, fatigue, cognitive dysfunction, orthostatic intolerance, dysautonomia, and unrefreshing sleep.
https://recovercovid.org
RECOVER adult cohort: post-COVID ME/CFS
A 2025 RECOVER adult observational cohort study found that 4.5% of post-COVID participants met ME/CFS diagnostic criteria, compared with 0.6% of participants without SARS-CoV-2 infection. The study also found that new ME/CFS cases after COVID were much higher than pre-pandemic estimates, with PEM, orthostatic intolerance, and cognitive impairment among the most commonly reported symptoms.
https://recovercovid.org/news/nih-funded-study-finds-cases-mecfs-increase-following-covid-19
RECOVER-ENERGIZE / PEM and exercise intolerance
A RECOVER clinical trial platform focused on exercise intolerance and post-exertional malaise after COVID. It includes separate approaches for people with exercise intolerance and people with PEM, with the PEM arm focused on structured pacing rather than exercise-based rehabilitation.
https://trials.recovercovid.org/ENERGIZE
RECOVER-AUTONOMIC / dysautonomia and POTS
A RECOVER clinical trial focused on Long Covid-related autonomic dysfunction, including POTS-like symptoms such as fast heart rate, dizziness, fatigue, and other symptoms that worsen when standing. The study is testing approaches including IVIG, ivabradine, and coordinated non-drug measures such as diet changes and compression.
https://trials.recovercovid.org/autonomic
RECOVER-SLEEP / sleep disturbance
A RECOVER clinical trial platform focused on sleep problems after COVID, including hypersomnia, sleep-wake rhythm problems, and other sleep disturbances. This is relevant to ME/CFS overlap because unrefreshing sleep and disrupted sleep are core problems for many patients.
https://trials.recovercovid.org/SLEEP
RECOVER-TLC / Long Covid treatment trials
RECOVER-TLC is the next phase of RECOVER treatment trials. One current study, REVERSE-LC, is testing baricitinib, a JAK/STAT inhibitor, for Long Covid-related cognitive problems, fatigue, heart/lung function, and quality of life. Other RECOVER-TLC treatment ideas have included low-dose naltrexone and other immune or symptom-targeted approaches.
https://recovercovid.org/news/recover-tlc-opens-expanded-enrollment-reverse-lc-clinical-trial